Promoter polymorphism of IL-10 and severity of multiple sclerosis

Acta Neurologica Scandinavica

Volumn 108, Issue 6, 2003, Pages 396-400

  Luomala, M ^a,b   Lehtimaki T ^a   Huhtala, H ^c   Ukkonen, M ^a,b   Koivula, T ^a   Hurme, M ^b   Elovaara, I ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Gene polymorphism; Genetic susceptibility; IL 10; Multiple sclerosis; Severity

Indexed keywords

CHEMOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); SEVERITY OF ILLNESS INDEX;

EID: 0344873093     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00165.x     Document Type: Article

References (38)

1. LASSMANN H, RAINE CS, ANTEL J, PRINEAS JW. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998;86:213-17.
2. MILLER SA, DYKES DD, POLESKY HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
3. HUANG Y, PAXTON WA, WOLINSKY SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3.
4. HELMINEN M, LAHDENPOHJA N, HURME M. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis 1999;180:496-9.
5. DONNER H, RAU H, WALfISH PG et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997;82: 143-6.
6. WILSON AG, DI GIOVINE FS, BLAKEMORE AI, DU GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992;1:353.
7. WEINSHENKER BG, RICE GP, NOSEWORTHY JH, CARRIERE W, BASKERVILLE J, EBERS GC. The natural history of multiple sclerosis: a geographically based study 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-56.
8. WESTENDORP RG, LANGERMANS JA, HUIZINGA TW et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3.
9. KUBE D, PLATZER C, VON KNETHEN A et al. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995;7:1-7.
10. TURNER DM, WILLIAMS DM, SANKARAN D, LAZARUS M, SINNOTT PJ, HUTCHINSON IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8.
11. EDWARDS-SMITH CJ, JONSSON JR, PURDIE DM, BANSAL A, SHORTHOUSE C, POWELL EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30:526-30.
12. HO AS, MOORE KW. Interleukin-10 and its receptor. Ther Immunol 1994;1:173-85.
13. LALANI I, BHOL K, AHMED AR. Interleukin-10: biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol 1997;79:469-83.
14. RIECKMANN P, ALBRECHT M, KITZE B et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-6.
15. RIECKMANN P, ALBRECHT M, KITZE B et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-8.
16. BOXEL-DEZAIRE VAN AH, HO SC, VAN OOSTEN BW et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis [see comments]. Ann Neurol 1999;45:695-703.
17. FEDORAK RN, GANGL A, ELSON CO et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000;119:1473-82.
18. SCHREIBER S, FEDORAK RN, NIELSEN OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 2000;119:1461-72.
19. MONTFRANS VAN C, FEDORAK R, GANGL A et al. Anti- and proinflammatory effects of interleukin-10 in mild to moderate Crohn's disease. Gastroenterology 1999;116:A777.
20. MAURER M, KRUSE N, GIESS R, TOYKA KV, RIECKMANN P. Genetic variation at position -1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis. J Neuroimmunol 2000;104:98-100.
21. PICKARD C, MANN C, SINNOTT P et al. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. J Neuroimmunol 1999;101:207-10.
22. ALMERAS L, MERESSE B, SEZE J et al. Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. Eur Cytokine Netw 2002;13:200-6.
23. DE JONG B, WESTENDORP R, ESKDALE J, UITDEHAAG B, HUIZINGA T. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum Immunol 2002;63: 281-5.
24. STRUNK T, BUBEL S, MASCHER B, SCHLENKE P, KIRCHNER H, WANDINGER KP. Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients. Ann Neurol 2000;47:269-73.
25. SORENSEN TL, TANI M, JENSEN J et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-15.
26. JALONEN T, PULKKINEN K, UKKONEN M, SAARELA M, ELOVAARA I. Differential intracellular expression of CCR5 and chemokines in MS subtypes. J Neurol 2002;249:576-83.
27. BARCELLOS LF, SCHITO AM, RIMMLER JB et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 2000;51:281-8.
28. BENNETTS BH, TEUTSCH SM, BUHLER MM, HEARD RN, STEWART GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997;58:52-9.
29. SELLEBJERG F, MADSEN HO, JENSEN CV, JENSEN J, GARRED P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102:98-106.
30. KOUKI T, SAWAI Y, GARDINE CA, FISFALEN ME, ALEGRE ML, DEGROOT LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-11.
31. HARBO HF, CELIUS EG, VARTDAL F, SPURKLAND A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999;53:106-10.
32. LIGERS A, XU C, SAARINEN S, HILLERT J, OLERUP O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999;97:182-90.
33. HE B, NAVIKAS V, LUNDAHL J, SODERSTROM M, HILLERT J. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol 1995;63:143-7.
34. WINGERCHUK D, LIU Q, SOBELL J, SOMMER S, WEINSHENKER BG. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology 1997;49:626-8.
35. WEINSHENKER BG, WINGERCHUK DM, LIU Q, BISSONET AS, SCHAID DJ, SOMMER SS. Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 1997;49:378-85.
36. MYCKO M, KOWALSKI W, KWINKOWSKI M et al. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol 1998; 84:198-206.
37. MAURER M, KRUSE N, GIESS R, KYRIALLIS K, TOYKA KV, RIECKMANN P. Gene polymorphism at position -308 of the tumor necrosis factor alpha promotor is not associated with disease progression in multiple sclerosis patients. J Neurol 1999;246:949-54.
38. LUCOTTE G, BATHELIER C, MERCIER G et al. TNF-alpha polymorphisms in multiple sclerosis: no association with -238 and -308 promoter alleles, but the microsatellite allele all is associated with the disease in French patients. Mult Scler 2000;6:78-80.